Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

DRRX:US

2.1100 USD 0.4600 17.90%

As of 20:10:00 ET on 04/24/2015.

Snapshot for Durect Corp (DRRX)

Open: 2.6000 Day's Range: 2.0900 - 2.6500 Volume: 2,122,050
Previous Close: 2.5700 52wk Range: 0.6800 - 2.6500 1-Yr Rtn: +62.31%

Stock Chart for DRRX

No chart data available.
  • DRRX:US 2.1100
  • 1D
  • 1M
  • 1Y
2.5700
Interactive DRRX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DRRX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.1900
Est. EPS (USD) (12/2015) -0.2400
Est. PEG Ratio -
Market Cap (M USD) 245.74
Shares Outstanding (M) 116.46
30 Day Average Volume 947,113
Price/Book (mrq) 12.9612
Price/Sale (ttm) 12.1253
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DRRX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DRRX

Durect Corporation develops and commercializes pharmaceutical systems for the treatment of chronic diseases. The pharmaceutical systems provide therapy for chronic diseases or conditions by replacing multiple injection therapy or oral dosing, improving drug efficacy, reducing side effects, and ensuring dosing compliance.

Felix TheeuwesChairman/Chief Scientific OfcrJames E BrownPresident/CEO/Co-Founder
Matthew J HoganChief Financial OfficerJudy R JoiceSenior VP:Operations
More Company Profile & Key Executives for DRRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil